OLMA
Olema Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.11
+8.05%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 306.0K | — | — | — | — |
| Gross Profit | (306.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 190.2M | 157.7M | 124.5M | 86.1M | 82.3M |
| SG&A Expense | 30.8M | 21.0M | 17.7M | 18.8M | 24.7M |
| General & Admin Expense | 30.9M | 21.0M | 17.7M | 18.8M | 24.7M |
| Selling & Marketing Expense | (119.0K) | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 220.8M | 178.7M | 142.3M | 105.0M | 107.0M |
| Cost and Expenses | 221.1M | 178.7M | 142.3M | 105.0M | 107.0M |
| Operating Income (EBIT) | (221.1M) | (178.7M) | (142.3M) | (105.0M) | (107.0M) |
| Non-Operating | |||||
| Interest Income | 16.9M | 16.2M | 12.7M | 8.3M | 2.2M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 16.9M | 16.2M | 12.7M | 8.3M | 2.2M |
| Other Non-Op Income/Expense | 16.6M | 16.2M | 12.8M | 8.3M | 2.2M |
| Non-Operating Income (excl Interest) | (16.6M) | (16.2M) | (12.8M) | (8.3M) | (2.2M) |
| EBT (Pre-Tax Income) | (204.6M) | (162.5M) | (129.5M) | (96.7M) | (104.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (204.6M) | (162.5M) | (129.5M) | (96.7M) | (104.8M) |
| Earnings from Cont. Ops | (204.6M) | (162.5M) | (129.5M) | (96.7M) | (104.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (204.6M) | (162.5M) | (129.5M) | (96.7M) | (104.8M) |
| Per Share | |||||
| Basic EPS | ($2.12) | ($1.87) | ($2.20) | ($2.14) | ($2.62) |
| Diluted EPS | ($2.13) | ($1.87) | ($2.20) | ($2.14) | ($2.62) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 104.5M | 87.0M | 58.7M | 45.2M | 40.0M |
| Diluted Shares Outstanding | 104.5M | 87.0M | 58.7M | 45.2M | 40.0M |
| Profitability Metrics | |||||
| EBITDA | (204.1M) | (162.0M) | (129.1M) | (96.3M) | (104.4M) |
| D&A | 451.0K | 490.0K | 393.0K | 377.0K | 357.0K |
| EBIT | (204.6M) | (162.5M) | (129.5M) | (96.7M) | (104.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026